Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.22
NXTM's Cash to Debt is ranked higher than
78% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. NXTM: 3.22 )
NXTM' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 3.22

Equity to Asset 0.60
NXTM's Equity to Asset is ranked higher than
72% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. NXTM: 0.60 )
NXTM' s 10-Year Equity to Asset Range
Min: -4.58   Max: 0.89
Current: 0.6

-4.58
0.89
F-Score: 3
Z-Score: 4.77
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -7.66
NXTM's Operating margin (%) is ranked higher than
61% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.34 vs. NXTM: -7.66 )
NXTM' s 10-Year Operating margin (%) Range
Min: -37110   Max: -4.63
Current: -7.66

-37110
-4.63
Net-margin (%) -8.34
NXTM's Net-margin (%) is ranked higher than
62% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. NXTM: -8.34 )
NXTM' s 10-Year Net-margin (%) Range
Min: -36600   Max: -6.26
Current: -8.34

-36600
-6.26
ROE (%) -12.67
NXTM's ROE (%) is ranked higher than
60% of the 280 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. NXTM: -12.67 )
NXTM' s 10-Year ROE (%) Range
Min: -491.86   Max: -8.69
Current: -12.67

-491.86
-8.69
ROA (%) -7.85
NXTM's ROA (%) is ranked higher than
60% of the 293 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.71 vs. NXTM: -7.85 )
NXTM' s 10-Year ROA (%) Range
Min: -94.54   Max: -5.02
Current: -7.85

-94.54
-5.02
ROC (Joel Greenblatt) (%) -22.22
NXTM's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.05 vs. NXTM: -22.22 )
NXTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -637.26   Max: -19.91
Current: -22.22

-637.26
-19.91
Revenue Growth (3Y)(%) 5.50
NXTM's Revenue Growth (3Y)(%) is ranked higher than
75% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. NXTM: 5.50 )
NXTM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 373.3
Current: 5.5

0
373.3
EPS Growth (3Y)(%) -22.30
NXTM's EPS Growth (3Y)(%) is ranked higher than
59% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. NXTM: -22.30 )
NXTM' s 10-Year EPS Growth (3Y)(%) Range
Min: -34.6   Max: 1.1
Current: -22.3

-34.6
1.1
» NXTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NXTM Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen 1,081,000 sh (-5.89%)
» More
Q2 2014

NXTM Guru Trades in Q2 2014

RS Investment Management 1,717,328 sh (New)
Steven Cohen 973,200 sh (unchged)
» More
Q3 2014

NXTM Guru Trades in Q3 2014

Jim Simons 67,600 sh (New)
RS Investment Management 2,206,428 sh (+28.48%)
Steven Cohen 1,005,300 sh (+3.3%)
» More
Q4 2014

NXTM Guru Trades in Q4 2014

Jim Simons 126,990 sh (+87.86%)
RS Investment Management 2,301,042 sh (+4.29%)
Steven Cohen 495,200 sh (-50.74%)
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.09%$10.61 - $13.73 $ 18.1156%0
John Burbank 2012-09-30 New Buy0.09%$12.47 - $17.04 $ 18.1127%150000
Ron Baron 2012-06-30 Sold Out 0.02%$14.94 - $19.44 $ 18.1110%0
Ron Baron 2012-03-31 New Buy0.02%$16.55 - $21.54 $ 18.111%176418
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 39.53
NXTM's Forward P/E is ranked higher than
76% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.95 vs. NXTM: 39.53 )
N/A
P/B 6.00
NXTM's P/B is ranked higher than
61% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. NXTM: 6.00 )
NXTM' s 10-Year P/B Range
Min: 0.8   Max: 14.22
Current: 6

0.8
14.22
P/S 3.80
NXTM's P/S is ranked higher than
67% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.94 vs. NXTM: 3.80 )
NXTM' s 10-Year P/S Range
Min: 0.66   Max: 16.71
Current: 3.8

0.66
16.71
EV-to-EBIT -48.76
NXTM's EV-to-EBIT is ranked higher than
64% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.92 vs. NXTM: -48.76 )
NXTM' s 10-Year EV-to-EBIT Range
Min: -72.2   Max: -2
Current: -48.76

-72.2
-2
Current Ratio 2.88
NXTM's Current Ratio is ranked higher than
76% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.73 vs. NXTM: 2.88 )
NXTM' s 10-Year Current Ratio Range
Min: 1.71   Max: 10.48
Current: 2.88

1.71
10.48
Quick Ratio 1.85
NXTM's Quick Ratio is ranked higher than
73% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. NXTM: 1.85 )
NXTM' s 10-Year Quick Ratio Range
Min: 0.75   Max: 9.59
Current: 1.85

0.75
9.59
Days Inventory 84.81
NXTM's Days Inventory is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 130.16 vs. NXTM: 84.81 )
NXTM' s 10-Year Days Inventory Range
Min: 80.86   Max: 611.57
Current: 84.81

80.86
611.57
Days Sales Outstanding 33.95
NXTM's Days Sales Outstanding is ranked higher than
95% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.21 vs. NXTM: 33.95 )
NXTM' s 10-Year Days Sales Outstanding Range
Min: 26.56   Max: 190.16
Current: 33.95

26.56
190.16

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.65
NXTM's Price/Tangible Book is ranked higher than
70% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.75 vs. NXTM: 8.65 )
NXTM' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 106.11
Current: 8.65

2.39
106.11
Price/Median PS Value 1.03
NXTM's Price/Median PS Value is ranked higher than
82% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. NXTM: 1.03 )
NXTM' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 3.79
Current: 1.03

0.23
3.79
Earnings Yield (Greenblatt) -2.10
NXTM's Earnings Yield (Greenblatt) is ranked higher than
60% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. NXTM: -2.10 )
NXTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.1   Max: 0
Current: -2.1

-2.1
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:N5X.Germany,
NxStage Medical, Inc., was incorporated in Delaware in 1998 under the name QB Medical, Inc., and later changed its name to NxStage Medical, Inc. NxStage is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its main product, the NxStage System One was designed to satisfy an unmet clinical need for a system that could deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that could be used by healthcare professionals and trained lay users alike in a number of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent, or 'daily,' dialysis. The System One is cleared by the United States Food and Drug Administration for home hemodialysis as well as hospital and clinic-based dialysis. It also sells needles and blood tubing sets mainly to dialysis clinics for the treatment of End Stage Renal Disease, or ESRD. The Company has two reporting segments, System One and In-Center. It distributes its products in three markets: the home, critical care and in-center. Within the System One segment, the Company sells and rentals System One and PureFlow SL equipment and sells disposable products in the home and critical care markets. The home market consists of dialysis centers that provide treatment options for patients that have ESRD, while the critical care market consists of hospitals or facilities that treat patients that have suddenly, and possibly temporarily, lost kidney function. The company sells essentially the same System One cyclers and disposables within each market and some of the company's largest customers in the home market provide outsourced renal dialysis services to hospitals in the critical care market to which the company sells System One cyclers and disposables. Sales of products to both markets are made through dedicated sales forces and products are distributed directly to the customer. Within the In-Center segment, the Company sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors. The Company competes with Fresenius, Gambro, Nipro, Baxter International, Inc., or Baxter, JMS and others. The Company is subject to government regulation in the countries in which it conducts business. In the foreign countries in which the Company market and sell its products, it is subject to local regulations affecting, among other things, design and product standards, packaging and labeling and promotion requirements.
» More Articles for NXTM

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
NxStage Medical Inc Earnings Call scheduled for 9:00 am ET today Feb 26 2015
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 26 2015
7:33 am Nxstage Medical beats by $0.02, beats on revs; guides FY15 revs in-line Feb 26 2015
NxStage Reports Record Fourth Quarter and Full-Year 2014 Revenue Feb 26 2015
Q4 2014 NxStage Medical Inc Earnings Release - Before Market Open Feb 26 2015
NxStage opens first two kidney care centers in Massachusetts Feb 25 2015
NxStage Kidney Care Brings Flexible Therapy Options To Greater Boston Area Feb 25 2015
NxStage Kidney Care Brings Flexible Therapy Options To Greater Boston Area Feb 25 2015
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog Feb 09 2015
NxStage Hosts Panel Discussion on Home Nocturnal Hemodialysis at 2015 Annual Dialysis Conference Feb 02 2015
NxStage Hosts Panel Discussion on Home Nocturnal Hemodialysis at 2015 Annual Dialysis Conference Feb 02 2015
Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog Jan 30 2015
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog Jan 29 2015
Mead Johnson's US Expansion Drives Q4 Earnings Beat - Analyst Blog Jan 29 2015
St. Jude Q4 Earnings Meet Estimates on Modest Sales Growth - Analyst Blog Jan 28 2015
NxStage® to Report Fourth Quarter and Full Year 2014 Financial Results Jan 28 2015
Stryker Lags Q4 Earnings, Revenue Estimates - Analyst Blog Jan 28 2015
NxStage® to Report Fourth Quarter and Full Year 2014 Financial Results Jan 28 2015
NxStage Establishes Annual Zenith Award To Recognize Excellence in Acute Renal Care Jan 20 2015
NxStage Establishes Annual Zenith Award To Recognize Excellence in Acute Renal Care Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK